{"denoms":[{"counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"12"}],"units":"Participants"}],"groups":[{"description":"Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nDasatinib: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies","id":"BG000","title":"Group I (Dasatinib)"},{"description":"Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nSunitinib: Given PO\n\nSunitinib Malate: Given PO","id":"BG001","title":"Group II (Sutinib Malate)"},{"description":"Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nSorafenib: Given PO\n\nSorafenib Tosylate: Given PO","id":"BG002","title":"Group III (Sorafenib Tosylate)"},{"description":"Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nPonatinib: Given PO\n\nPonatinib Hydrochloride: Given PO","id":"BG003","title":"Group IV (Ponatinib Hydrochloride)"},{"description":"Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPacritinib: Given PO\n\nPharmacological Study: Correlative studies","id":"BG004","title":"Group V (Pacritinib)"},{"description":"Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nRuxolitinib: Given PO","id":"BG005","title":"Group VI (Ruxolitinib)"},{"description":"Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nIdelalisib: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies","id":"BG006","title":"Group VII (Idelalisib)"},{"description":"Total of all reporting groups","id":"BG007","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"69","upperLimit":"74","value":"70.5"},{"groupId":"BG001","lowerLimit":"47","upperLimit":"53","value":"50"},{"groupId":"BG002","lowerLimit":"31","upperLimit":"72","value":"57.5"},{"groupId":"BG007","lowerLimit":"31","upperLimit":"74","value":"63"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"},{"groupId":"BG007","value":"7"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG007","value":"5"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"},{"groupId":"BG007","value":"9"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG007","value":"3"}],"title":"Hispanic or Latino"}],"title":"Race/Ethnicity"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Zero patients were enrolled in the Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms."}